Lamivudine Teva Pharma (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which competes with natural nucleosides for incorporation into viral DNA. This results in premature chain termination, blocking HIV‑1 reverse transcriptase and hepatitis B virus DNA polymerase activity.

The dosage of lamivudine is individualized by the prescribing clinician based on the patient’s condition, weight, renal function, and other factors. Patients should follow the exact regimen provided by their healthcare professional.

Lamivudine is classified as pregnancy category B, indicating no evidence of risk in animal studies and limited human data. It may be used when the therapeutic benefit justifies potential risks. Small amounts are excreted in breast milk; clinicians should weigh benefits and monitor the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with older NRTIs, it has a favorable safety profile, lower mitochondrial toxicity, and is active against both HIV‑1 and hepatitis B virus.

Lamivudine tablets should be stored at room temperature, below 25 °C, in the original container to protect from moisture and light. Do not store in humid or excessively hot environments.

Lamivudine Teva is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious adverse events, though rare, include lactic acidosis, hepatic steatosis, severe skin reactions such as Stevens‑Johnson syndrome, pancreatitis, neutropenia, and anemia. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or severe skin rash.

Lamivudine is contraindicated in patients with known hypersensitivity to lamivudine or any of its excipients. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in combination with contraindicated drugs such as didanosine or stavudine.